Press coverage about NanoString Technologies (NASDAQ:NSTG) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NanoString Technologies earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 44.8601170592972 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
NSTG has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of NanoString Technologies from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Wednesday, January 3rd. ValuEngine cut shares of NanoString Technologies from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 price objective (down from $13.00) on shares of NanoString Technologies in a report on Thursday, March 8th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. NanoString Technologies has an average rating of “Hold” and an average price target of $13.06.
Shares of NanoString Technologies stock opened at $6.55 on Thursday. The company has a quick ratio of 2.84, a current ratio of 3.40 and a debt-to-equity ratio of 1.22. NanoString Technologies has a fifty-two week low of $5.87 and a fifty-two week high of $20.70. The stock has a market cap of $174.01, a price-to-earnings ratio of -3.52 and a beta of 0.91.
In other news, Director William Young purchased 30,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The stock was bought at an average cost of $6.91 per share, for a total transaction of $207,300.00. Following the completion of the acquisition, the director now directly owns 30,000 shares of the company’s stock, valued at $207,300. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 24.40% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact NanoString Technologies (NSTG) Stock Price” was posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://baseballnewssource.com/2018/03/22/nanostring-technologies-nstg-earning-somewhat-favorable-news-coverage-study-finds/1925845.html.
About NanoString Technologies
NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.